The Clorox Recall Lawsuit Reaches Oakland: 6.3 Million Bottles and a Refund Program on Trial

The Clorox recall lawsuit: a territorial class over 6.3 million bottles lands in Oakland

On 24 September 2026 Puerto Rico purchasers filed a putative Class Action against The Clorox Company in the United States District Court for the Northern District of California, docketed as Rivera Toro et al. v. The Clorox Company, No. 4:26-cv-10893, over the recall of roughly 6.3 million bottles of Scented Mistolin dilutable cleaners and Lestoil heavy-duty multi-purpose cleaners that may carry Pseudomonas aeruginosa. The Clorox recall lawsuit does not allege that anyone has been infected. It alleges that the company sold a product it had reason to suspect was contaminated, that the refund now on offer is worth less than what buyers gave up, and that a recall aimed at a Spanish-speaking market was not adequately communicated in Spanish.

That framing matters more than the bacterium. Nothing in this case turns on epidemiology, expert gatekeeping or a bellwether queue. It turns on whether a court will certify a class of consumers who bought a cleaning product in Puerto Rico and the U.S. Virgin Islands, under California statutes, against a company that has already offered every one of them a full refund. Those are the three pressure points, and each of them has appellate authority pointing in an awkward direction for the plaintiffs.

Reported accounts differ slightly on who the named purchasers are. Law360 describes a pair of Puerto Rico buyers, identifying Carolina Rivera Toro and Stephanie Barbosa; Courthouse News Service describes the action as brought by Leslie Santana, a citizen of Puerto Rico. The docket caption is Rivera Toro et al., which is consistent with more than one Named Plaintiff. The complaint itself was not available for inspection, so this analysis treats the caption as controlling and the individual attributions as reported.

The claims, as both outlets describe them, are California's Unfair Competition Law, California's False Advertising Law and the Consumers Legal Remedies Act, together with fraudulent concealment, breach of implied warranty against hidden defects, and unjust enrichment. The proposed class reaches anyone who bought a recalled bottle in Puerto Rico or the U.S. Virgin Islands on or after 1 April 2025 — potentially hundreds of thousands of buyers, and on the plaintiffs' own framing possibly millions. The relief sought is broader than money: disclosure of the contamination risk, strengthened testing protocols, and recall notices in Spanish.

Which Clorox products were recalled in September 2026?

The Consumer Product Safety Commission posted the recall on 3 September 2026, three weeks before the complaint. The recalling firm is Clorox Manufacturing Company of Puerto Rico, Inc., and the products were never sold on the mainland — a detail that shapes every jurisdictional question in the case.

Item	Detail
Recall posted	3 September 2026 (CPSC recall 26-741)
Units	Approximately 6.3 million
Scented Mistolin dilutable cleaners	Alegra tu Día, Espíritu Play, Flores de Primavera, Fresco Despertar, Frescura de Lavanda, Frescura Tropical, Manzana y Canela, Pino y Especias, Sólo para Ti
Lestoil heavy-duty multi-purpose cleaners	Energía del Yunque, Fuerza de Lavanda Tropical, Intenso Limón Boricua, Olas de Rincón
Bottle sizes	28, 40, 64 and 128 fluid ounces
Date codes	Prefix "PR01" followed by a five-digit number from 25091 to 26168
Production window	1 April 2025 to 17 June 2026
Retail price	$1.40 to $8
Where sold	Puerto Rico and the U.S. Virgin Islands — Walmart, Sam's Club, Costco, Supermercados Econo, Supermercados Selectos and others
Reported incidents or injuries	None as of the recall notice
Remedy	Full refund of the purchase price with a receipt, or of the suggested retail price without one, after registering at mistolinrecall.expertinquiry.com and disposing of the bottle
Consumer line	Clorox Puerto Rico, 855-215-5439

Two features of that table do most of the work in the litigation. The first is the zero in the incidents row: a recall notice that reports no injuries is a recall notice that makes a personal-injury docket very hard to build, and pushes counsel toward the economic-loss theory that was in fact pleaded. The second is the refund. Clorox is not defending a market it refuses to compensate; it is defending a market it has already offered to pay, receipt or no receipt. That converts the case from a liability fight into a Rule 23 fight.

What is Pseudomonas aeruginosa, and why does it matter in a household cleaner?

Pseudomonas aeruginosa is a common environmental bacterium found in soil and water, and for most people with an intact immune system it is unremarkable. The risk is concentrated in a narrower population: people who are immunocompromised, and people with external medical devices such as catheters or ventilators. The CPSC notice describes three routes of entry — inhalation, contact with the eyes, and contact through broken skin — and warns that exposure can cause a serious infection requiring medical treatment.

The organism's reputation comes from hospitals rather than kitchens. The Centers for Disease Control and Prevention attributes roughly 51,000 healthcare-associated infections in the United States each year to P. aeruginosa, and estimated that multidrug-resistant strains caused about 32,600 infections among hospitalized patients and some 2,700 deaths in 2017. The rate of multidrug-resistant cases rose about 32 per cent between 2019 and 2020. Some strains resist nearly every available antibiotic, carbapenems included.

That epidemiology explains why a cleaning-product contamination is treated as a safety defect rather than a cosmetic one, and it explains the shape of the plaintiffs' injunctive demand for stronger testing. It does not, however, supply a General Causation case for any individual claimant, because the exposure pathway from a diluted floor cleaner to a diagnosed infection is neither documented in the recall notice nor established anywhere in the public record of this litigation.

Did Clorox know about the contamination before the recall?

This is the allegation that gives the complaint its punitive edge, and it rests on a documented corporate history rather than on inference.

Date	Event
Early 2019	Clorox microbiologists reported that storage tanks and finished Pine-Sol product may have contained bacteria described internally as possibly a Pseudomonad
25 October 2022	Clorox and the CPSC jointly announced the recall of roughly 37 million bottles of Pine-Sol Scented Multi-Surface Cleaning Products over possible bacterial contamination
2023–2024	Consumer class litigation over the Pine-Sol recall resolved for $5.65 million, with a final approval hearing held on 22 May 2024 and a class period running from 1 November 2018 to 15 November 2023
27 January 2026	The CPSC announced that Clorox agreed to pay a $14.15 million civil penalty for failing to report immediately that the Pine-Sol products contained a defect that could create a substantial product hazard or an unreasonable risk of serious injury or death
1 April 2025 – 17 June 2026	The recalled Mistolin and Lestoil bottles were produced in Puerto Rico
3 September 2026	The CPSC posted the Mistolin and Lestoil recall covering about 6.3 million bottles
24 September 2026	Rivera Toro et al. v. The Clorox Company filed in the Northern District of California

Read in sequence, the timeline is the plaintiffs' best asset. The company had encountered the same organism in the same product category, had been penalised by the federal regulator for not reporting it quickly enough, and — critically — was producing the Mistolin and Lestoil units during and after the period in which the penalty was negotiated and announced. Law360's account of the complaint puts the point as a duty to disclose arising from the earlier recall combined with the company's own internal testing.

The duty-to-disclose framing is doing double work. It supports Failure to Warn and fraudulent concealment theories on the merits, and it supports the argument that the recall came too late to discharge the obligation. Section 15(b) of the Consumer Product Safety Act requires a manufacturer to report immediately on learning that a product contains a defect that could create a substantial product hazard. A regulator's finding that the company breached that duty once, in a matter involving the same bacterium, is not a finding about this recall — but it is the kind of prior act that shapes discovery requests, deposition outlines and any eventual Punitive Damages theory.

Does the Clorox refund program stop the class action?

This is the question the case will actually be decided on, and the answer is more interesting than either side's press framing suggests.

The intuitive defence argument is that a full-refund program administered through a Claims Administrator is simply a better mechanism than a lawsuit: it is faster, it costs the class nothing, and it does not route a third of the recovery through a Contingency Fee. Defendants have made that argument since In re Aqua Dots Products Liability Litigation, 654 F.3d 748 (7th Cir. 2011), where the district court denied Class Certification on the view that the manufacturer's reimbursement scheme distributed refunds more efficiently than a class judgment would.

The Seventh Circuit's actual holding is narrower and cuts both ways. Writing for the panel, Chief Judge Easterbrook rejected the superiority rationale: Rule 23(b)(3) requires a court to compare a class action with other available judicial proceedings, not with a company's voluntary out-of-court program. Superiority is a comparison among litigation vehicles. On that reasoning, a refund scheme cannot by itself defeat certification.

The court nonetheless affirmed the denial, on adequacy. Under Rule 23(a)(4) a representative who pursues a remedy that is worse for the class than an alternative already available to it is not adequately protecting the class's interests. That is the doorway defendants will use here: not "the refund is superior" but "these representatives are chasing a smaller recovery than the refund already delivers."

The plaintiffs' answer is visible in the relief they sought. They do not ask only for money. They ask for disclosure, for strengthened testing, and for Spanish-language recall notices — three things a refund program does not provide. The Spanish-language demand is the sharpest of them. A recall confined to Puerto Rico and the U.S. Virgin Islands, remediated through an English-language web registration portal that asks consumers to photograph a twelve-digit UPC and a date code, is straightforwardly vulnerable to an argument that the notice mechanism under-serves the very market it was designed for. If the refund program reaches only a fraction of 6.3 million bottles, the adequacy objection weakens, because the class representatives are then offering something the program is failing to deliver.

Expect the certification briefing to fight over take-up rates rather than over microbiology. Redemption data from the registration portal will be the most consequential discovery in the case.

Why is a Puerto Rico class action filed in a California court?

Clorox is headquartered in Oakland, which sits in the Northern District of California, so the forum is the defendant's home. Puerto Rico purchasers can be in federal court there without difficulty: 28 U.S.C. § 1332(e) provides that the word "States" in the diversity statute includes the Territories, the District of Columbia and the Commonwealth of Puerto Rico. Aggregating millions of small-dollar claims also comfortably clears the Class Action Fairness Act (CAFA) threshold of $5 million in the aggregate, which is how a dispute over bottles priced between $1.40 and $8 becomes a federal case at all. Each individual claim is a textbook Negative-Value Claim; only aggregation makes it viable.

The harder problem is not the forum. It is the law.

A class of Puerto Rico and Virgin Islands buyers suing under California's Unfair Competition Law, False Advertising Law and Consumers Legal Remedies Act runs directly into Mazza v. American Honda Motor Co., 666 F.3d 581 (9th Cir. 2012). Applying California's governmental-interest test, the Ninth Circuit held that the jurisdiction with the greatest interest in supplying the rule of decision is the one where the consumer received the representations, made the purchase and suffered the loss — not the jurisdiction from which the corporate conduct emanated. A defendant's extensive California contacts, including its headquarters, do not displace that analysis. Mazza decertified a nationwide class for exactly this reason, and it remains the first authority a Clorox brief will cite.

If Mazza controls, Puerto Rico's own consumer-protection regime supplies the rule of decision for Puerto Rico purchasers, and Virgin Islands law for the others. That is not fatal — a two-jurisdiction class is a long way from the forty-four-jurisdiction problem in Mazza, and Predominance is easier to defend across two bodies of law than across fifty. But it changes the shape of the case. It puts a Commonwealth statutory scheme and a territorial one in front of a California judge, invites sub-classing, and gives the defence a clean argument that the California statutes the plaintiffs chose do not reach these purchases at all. Reported accounts describe the pleading as seeking both a nationwide class and a Puerto Rico sub-class, which suggests counsel has anticipated the problem; whether a nationwide class survives when the product was never sold nationwide is a different question, and a short one.

Ascertainability, by contrast, should be unusually easy here. The class is defined by a product that existed only in two territories, for a fourteen-month production window, with printed date codes identifying the affected units. Product Identification problems that plague most consumer-product classes are largely absent.

How much could the Clorox recall lawsuit be worth?

No competitor page computes this, so it is worth doing plainly. The recall covers about 6.3 million units at a retail price of $1.40 to $8.

Measure	Low	High
Units recalled	6.3 million	6.3 million
Unit price	$1.40	$8.00
Full-refund restitution if every unit is claimed	about $8.8 million	about $50.4 million
Statutory or punitive multiplier	not quantifiable on the public record	not quantifiable on the public record

Two caveats matter. Not every recalled bottle was sold — a recall count is a production and distribution figure, not a purchase figure — so the true restitution ceiling sits below the high end. And every dollar Clorox pays through the refund portal is a dollar off the class's recoverable restitution, which is precisely why the defence wants the portal to work and the plaintiffs want its take-up rate disclosed.

The figures explain the litigation's economics. A restitution class capped in the low tens of millions does not support years of expert discovery. It supports an early motion to dismiss on choice of law, a certification fight about adequacy and notice, and then a negotiated resolution. The Pine-Sol comparison is instructive: a recall of roughly 37 million bottles — nearly six times the size of this one — produced a $5.65 million consumer class settlement alongside a $14.15 million regulatory penalty. The regulator, not the class, extracted the larger number.

Can I sue Clorox if I got sick from Mistolin or Lestoil?

The economic-loss class and any personal-injury claim are separate cases with separate difficulties, and conflating them is the most common error in the consumer-facing coverage of this recall.

A purchaser who simply owns a recalled bottle has an economic claim: the benefit of the bargain, measured by the price paid for a product alleged to be worth less than represented. That claim needs no medical evidence and is the claim actually pleaded.

A claimant who developed a P. aeruginosa infection faces a materially harder case, and one that would not belong in this class action. They would need Product Identification tying the infection to a bottle within the recalled date-code range, General Causation evidence that diluted household cleaner is a plausible transmission route for this organism, and Specific Causation evidence excluding the far more common healthcare-associated pathways that account for the CDC's 51,000 annual infections. The recall notice's statement that no incidents or injuries have been reported does not preclude such a claim, but it tells you how thin the current evidentiary base is. No personal-injury filing over this recall has been publicly reported.

Practitioners should also note what is absent. A bottle of floor cleaner bought off a supermarket shelf carries no Arbitration Clause and no Class Action Waiver. There is no delegation fight, no mass-filing threat, no provider-fee leverage — none of the machinery that now dominates app-mediated consumer disputes. Physical-goods recalls remain one of the few consumer categories where Rule 23 is still the whole game, which is why the doctrinal action here is in Aqua Dots and Mazza rather than in the Federal Arbitration Act.

Will the Clorox recall cases become an MDL?

Probably not, and the reason is structural. Multidistrict Litigation (MDL) exists to coordinate actions scattered across districts. This product was sold in two territories and the defendant is headquartered in one district, so parallel filings will naturally cluster in the Northern District of California, where the local rules on related cases can consolidate them without troubling the Judicial Panel on Multidistrict Litigation (JPML). Centralization becomes plausible only if a genuine personal-injury inventory develops in the District of Puerto Rico and the District of the Virgin Islands alongside the California consumer docket — and on the current record, that inventory does not exist.

The likelier trajectory is a consolidated amended complaint, a motion to dismiss aimed squarely at the extraterritorial reach of the California statutes, and a certification motion in which the refund portal's redemption data decides the adequacy question. The Statute of Limitations is not a near-term constraint: purchases began on 1 April 2025 and the recall is three weeks old.

What the Clorox recall lawsuit means for defense counsel, plaintiffs' firms and recall managers

For product-side defence counsel. A refund program is a partial shield, not a complete one, and Aqua Dots explains exactly which part of Rule 23 it operates on. Do not brief it as superiority; brief it as adequacy under Rule 23(a)(4), and build the record on redemption rates early. A voluntary remedy that no one claims is an argument that defeats itself.

For recall managers and in-house teams. The notice channel is now a litigable design choice. A recall confined to a Spanish-speaking market, remediated through an English web portal requiring UPC and date-code photography, hands the plaintiffs an injunctive claim that survives every payment the program makes. Language, literacy and receipt-free proof routes belong in the recall plan, not in the post-filing remediation.

For plaintiffs' firms. The value of this case is in the injunctive relief and the knowledge allegation, not in the restitution arithmetic. The prior-recall-and-penalty sequence is the asset; the $1.40-to-$8 unit price is the ceiling. Choose the governing law deliberately rather than defaulting to California statutes because the defendant is headquartered there, because Mazza will make that choice expensive.

For anyone tracking the recall-to-litigation pipeline. Twenty-one days elapsed between a CPSC posting and a federal class complaint. That interval, not the science, is the practical measure of how quickly a Mass Tort or consumer docket forms around a modern recall.

Frequently asked questions

What is the Clorox recall lawsuit about?

It is a putative class action filed on 24 September 2026 in the Northern District of California, Rivera Toro et al. v. The Clorox Company, No. 4:26-cv-10893, alleging that Clorox sold about 6.3 million bottles of Mistolin and Lestoil cleaners that risked Pseudomonas aeruginosa contamination, that it should have known of the risk sooner given a 2022 Pine-Sol recall over the same organism, and that its refund program falls short of making buyers whole.

Who can join the Clorox recall class action?

As proposed, the class covers anyone who purchased one of the recalled Mistolin or Lestoil products in Puerto Rico or the U.S. Virgin Islands on or after 1 April 2025. No class has been certified, so nothing is decided; purchasers remain free to use the refund program in the meantime.

Does the Clorox refund program stop the class action?

Not by itself. Under In re Aqua Dots, a company's voluntary refund scheme is not a competing "judicial proceeding" for Rule 23(b)(3) superiority purposes. But the same decision affirmed denial of certification on adequacy grounds where the representatives sought a remedy inferior to the one already available, and that is the argument Clorox is likeliest to run.

Which products and date codes are affected?

Nine Scented Mistolin dilutable cleaner varieties and four Lestoil heavy-duty multi-purpose cleaner varieties, in 28, 40, 64 and 128 fluid ounce bottles, bearing date codes beginning "PR01" followed by a five-digit number between 25091 and 26168 — products made between 1 April 2025 and 17 June 2026.

Has anyone been injured by the recalled cleaners?

The CPSC recall notice reports no incidents and no injuries as of its posting on 3 September 2026. That is one reason the pleaded claims are economic rather than personal-injury claims.

Why does a 2022 Pine-Sol recall matter to a 2026 Mistolin case?

Because it supplies knowledge. Clorox recalled roughly 37 million bottles of scented Pine-Sol on 25 October 2022 over the same organism, and on 27 January 2026 the CPSC announced a $14.15 million civil penalty for the company's failure to report that defect immediately — a finding the plaintiffs use to argue that the duty to disclose in this recall attached well before 3 September 2026.

This report is analysis of public filings, a federal recall notice and published authority. It is not legal advice.